WASHINGTON (dpa-AFX) - After gapping open sharply higher, shares of Sarepta Therapeutics (SRPT) continue to see significant strength in afternoon trading on Wednesday. Sarepta is up by 18.2 percent after reaching its best intraday level in over a month.
The jump by Sarepta comes after the company was notified that the FDA will be unable to complete its review of the new drug application for eteplirsen by the goal date of May 26th.
Copyright RTT News/dpa-AFX